Orion Corporation: Decisions by the AGM on 24 March 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Orion Corporation: Decisions by the AGM on 24 March 2015

ORION CORPORATION      STOCK EXCHANGE RELEASE   24 MARCH 2015 3.30 p.m. EET Orion Corporation: Decisions by the AGM on 24 March 2015 At the Annual General Meeting of Orion Corporation held today, the following decisions were made: * A dividend of EUR 1.30 per share was confirmed to be paid for 2014. The record date for the dividend payment is 26 March 2015 and the payment date is 2 April 2015. * The proposals concerning the election and remuneration of the Board of Directors and the auditor and the number of the members of the Board of Directors were approved. * Sirpa Jalkanen, Eero Karvonen, Timo Maasilta, Mikael Silvennoinen, Hannu Syrjänen, Heikki Westerlund and Jukka Ylppö were re-elected to the Board of Directors. Hannu Syrjänen was re-elected as Chairman. The Annual General Meeting of Orion Corporation was held today in Helsinki. The following matters were handled at the meeting: Adoption of the Financial Statements for 1 January - 31 December 2014 The AGM confirmed the Financial Statements of the parent company and the Group as per 31 December 2014. Dividend EUR 1.30 per share The proposed dividend of EUR 1.30 per share was approved. The record date for the dividend payment is 26 March 2015 and the payment date is 2 April 2015. Discharge from liability The members of the Board of Directors and the President and CEO were discharged from liability for the financial period of 1 January - 31 December 2014. Remunerations to be paid to the Board of Directors As an annual fee for the term of office of the Board of Directors, the Chairman shall receive EUR 76,000, the Vice Chairman shall receive EUR 51,000 and the other members shall receive EUR 38,000 each. As a fee for each meeting attended, the Chairman shall receive EUR 1,200, the Vice Chairman shall receive EUR 900 and the other members shall receive EUR 600 each. The travel expenses of all Board members shall be paid in accordance with previously adopted practice. The afore- mentioned fees for each committee meeting attended shall also be paid to the Chairmen and to the members of the committees established by the Board. Of the annual fee, 60% shall be paid in cash and 40% in Orion Corporation B- shares, which shall be acquired to the members during 30 March - 2 April 2015 from the stock exchange in amounts corresponding to EUR 30,400 for the Chairman, EUR 20,400 for the Vice Chairman and EUR 15,200 for each of the other members. The part of the annual fee that is to be paid in cash corresponds to the approximate sum necessary for the payment of the income taxes on the fees and shall be paid no later than 30 April 2015. The annual fees encompass the full term of office of the Board of Directors. Composition of the Board of Directors Hannu Syrjänen re-elected as Chairman The number of members in the Board of Directors was confirmed to be seven. Sirpa Jalkanen, Eero Karvonen, Timo Maasilta, Mikael Silvennoinen, Hannu Syrjänen, Heikki Westerlund and Jukka Ylppö were re-elected to the Board of Directors for the next term of office. Hannu Syrjänen was re-elected as Chairman. Auditor and their remuneration PricewaterhouseCoopers Oy, authorised public accountants, were re-elected as the Company's auditor. The remunerations to the Auditor shall be paid on the basis of invoicing approved by the Company. The minutes of the AGM will be provided in Finnish only, and they will become available on Orion's website, http://www.orion.fi/agm2015, no later than 7 April 2015. Orion Corporation Timo Lappalainen                          Olli Huotari President and CEO                        Senior Vice President, Corporate Functions Contact person: Olli Huotari, Senior Vice President, Corporate Functions, phone +358 50 966 3054 Publisher: Orion Corporation Communications Orionintie 1A, FI-02101 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki. [HUG#1905478]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 98

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading

Top 5 Most Recently Viewed Articles

Ross Gerber Expresses Optimism for Meta's Phone-Free Future

Updated Category News Views 242

Ross Gerber Praises Meta's Smart Glasses Technology Over the weekend, investor Ross Gerber expressed his admiration for Meta Platforms, Inc. (NASDAQ: META) smart glasses, affirming their potential to transform our relationship with technology. Gerber noted that this innovative eyewear gives him hope for a day when he might no longer rely on his smartphone. Smart Glasses:...

Continue Reading
Organ-on-a-Chip Market Insights and Future Projections

Updated Category News Views 118

Understanding the Organ-on-a-Chip Market Growth As technology evolves, the quest for more accurate and human-relevant drug testing models takes center stage. The Organ-on-a-Chip (OOC) market has emerged as a revolutionary force, previously valued at around USD 117.67 million, and now set to skyrocket to approximately USD 1.64 billion by 2032. This innovative approach is...

Continue Reading
Discovering Blue Light Cystoscopy Benefits in Bladder Cancer

Updated Category News Views 240

New Insights on Blue Light Cystoscopy and Bladder Cancer Photocure ASA, known as the Bladder Cancer Company, has made significant advancements in bladder cancer management with the recent study titled "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO Study." This research published in JU Open Plus provides compelling evidence...

Continue Reading
BioCryst's Bold Move: Astria Therapeutics Acquisition Insights

Updated Category News Views 211

BioCryst Enhances HAE Portfolio with Astria Acquisition BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant announcement regarding its acquisition of Astria Therapeutics, Inc. (NASDAQ: ATXS). This strategic move will strengthen BioCryst's position in the hereditary angioedema (HAE) market, as they plan to integrate Astria's promising therapies and...

Continue Reading
Milestone Scientific Reaches New Height with Strong Growth

Updated Category News Views 361

Milestone Scientific Achieves 52-Week High Milestone Scientific Inc. (NYSE: MLSS) has reached a significant milestone with its stock trading at $1.28, marking a 52-week high. This impressive achievement highlights the company's robust annual growth and increased investor confidence. As a result, the current market capitalization has reached approximately $97.37 million,...

Continue Reading